Dowpharma Consolidates Biopharmaceutical Process Development to San Diego
The San Diego site, located in a regional biotech hub, will focus on the rapid process development and scale-up of client production processes for therapeutic proteins and peptides expressed in various systems. "The cutting-edge work at San Diego is exemplified by the development and recent launch of PROTEIN FACTORY, a novel Pseudomonas fluorescens based expression technology from Dowpharma, for the production of therapeutic proteins and peptides," says Nick Hyde, business director, Dowpharma.
"Integrating all of our biopharmaceutical customer process development activities will allow us to leverage the significant resources and expertise that exist within Dow's biotechnology R&D. It will enable us to offer our customers state-of-the-art capabilities. Dowpharma is committed to becoming a leader in biopharmaceutical contract manufacturing and will continue to invest in opportunities that will allow us to help make affordable medicines for our customers," states Hyde.
Topics
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.